ATE346068T1 - Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden - Google Patents

Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden

Info

Publication number
ATE346068T1
ATE346068T1 AT03744860T AT03744860T ATE346068T1 AT E346068 T1 ATE346068 T1 AT E346068T1 AT 03744860 T AT03744860 T AT 03744860T AT 03744860 T AT03744860 T AT 03744860T AT E346068 T1 ATE346068 T1 AT E346068T1
Authority
AT
Austria
Prior art keywords
quinoline
ligands
indole derivatives
aza indole
aza
Prior art date
Application number
AT03744860T
Other languages
English (en)
Inventor
Christopher Norbert Johnson
Gregor James Macdonald
Darren Jason Mitchell
Stephen Frederick Moss
Mervyn Thompson
David Witty
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207275A external-priority patent/GB0207275D0/en
Priority claimed from GB0207282A external-priority patent/GB0207282D0/en
Priority claimed from GB0207281A external-priority patent/GB0207281D0/en
Priority claimed from GB0207278A external-priority patent/GB0207278D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE346068T1 publication Critical patent/ATE346068T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
AT03744860T 2002-03-27 2003-03-25 Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden ATE346068T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0207275A GB0207275D0 (en) 2002-03-27 2002-03-27 Novel compounds
GB0207282A GB0207282D0 (en) 2002-03-27 2002-03-27 Novel compounds
GB0207281A GB0207281D0 (en) 2002-03-27 2002-03-27 Novel compounds
GB0207278A GB0207278D0 (en) 2002-03-27 2002-03-27 Novel compounds

Publications (1)

Publication Number Publication Date
ATE346068T1 true ATE346068T1 (de) 2006-12-15

Family

ID=28457826

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744860T ATE346068T1 (de) 2002-03-27 2003-03-25 Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden

Country Status (8)

Country Link
US (1) US20050124626A1 (de)
EP (1) EP1497291B1 (de)
JP (1) JP2005527542A (de)
AT (1) ATE346068T1 (de)
AU (1) AU2003226724A1 (de)
DE (1) DE60309852T2 (de)
ES (1) ES2277098T3 (de)
WO (1) WO2003080608A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
WO2004074286A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands
CN100422171C (zh) 2003-02-14 2008-10-01 惠氏公司 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
CN100439367C (zh) * 2003-12-11 2008-12-03 安万特药物公司 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
DK1753764T3 (da) 2004-06-09 2009-02-16 Glaxo Group Ltd Pyrrolopyridin-derivater
GB0425548D0 (en) * 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
BRPI0614483A2 (pt) * 2005-07-27 2011-03-29 Hoffmann La Roche ariloxiquinolinas e usos das mesmas como 5-ht6
CN101326187A (zh) * 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 吡咯并[2,3-c]吡啶衍生物
BRPI0709718A2 (pt) 2006-04-05 2011-03-29 Wyeth Corp composto; método para tratamento de um transtorno do sistema nervoso central relacionado a ou afetado pelo receptor 5-ht6 em um paciente necessitado; composição farmacêutica; e proceso para a preparação do composto
EP2254564A1 (de) 2007-12-12 2010-12-01 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
RU2369600C1 (ru) * 2008-01-24 2009-10-10 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーAxovant Sciences Gmbh レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
KR102351054B1 (ko) 2019-11-11 2022-01-14 엠비디 주식회사 신규한 퀴놀린 화합물 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
AU779832B2 (en) * 1999-08-12 2005-02-10 Nps Pharmaceuticals, Inc. Azaindoles having serotonin receptor affinity
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物
WO2004074286A1 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
WO2003080608A2 (en) 2003-10-02
US20050124626A1 (en) 2005-06-09
AU2003226724A1 (en) 2003-10-08
DE60309852T2 (de) 2007-06-06
EP1497291A2 (de) 2005-01-19
EP1497291B1 (de) 2006-11-22
AU2003226724A8 (en) 2003-10-08
JP2005527542A (ja) 2005-09-15
WO2003080608A3 (en) 2004-02-05
DE60309852D1 (de) 2007-01-04
ES2277098T3 (es) 2007-07-01

Similar Documents

Publication Publication Date Title
DE60309852D1 (de) Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
MY138836A (en) Quinoline derivatives and their use as 5-ht6 receptor ligands
BR0315547A (pt) Derivados de quinolina como antagonistas de crth2
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE293448T1 (de) Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten
ATE496884T1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
DE602005025642D1 (de) 3-(heteroaryloxy)-2-alkyl-1-azabicycloalkylderivate als alpha.7-nachr-liganden zur behandlung von zns-erkrankungen
TR199700749T1 (xx) 5-HT resept�r antagonisti olarak indole t�revleri.
HRP20020748A2 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
NO20044764L (no) 1-(aminoalkyl)-3-sulfonylindol og -indazolderivater som 5-hydroksytryptamin-6 ligander
ATE418550T1 (de) 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
ATE433966T1 (de) Methylendipiperidinderivate
TW200514781A (en) Novel compounds
GB0322510D0 (en) Novel compounds
BR0108088A (pt) Pirrolidinas 1,3-dissubstituìdas e 1,3,3-trissubstituìdas como ligandos receptores de histamina-3 e suas aplicações terapêuticas
IS8521A (is) Þríhringlaga indólhýdróxýetýlamínafleiður og notkun þeirra í meðhöndlun á Alzheimerssjúkdómi
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE60103856D1 (de) Thiazolopyrimidine und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
UY26426A1 (es) Nuevos compuestos
MXPA05004273A (es) Derivados de fenilalquil y piridilalquil piperazina.
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
ATE277010T1 (de) Bis-indolederivate und ihre verwendung als entzündungshemmende mittel
ATE386525T1 (de) 3-substituierte 6,7- dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties